In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 10 of 13

TitleConsultationTypeConsultation end date
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332]Draft guidanceTechnology appraisal guidance
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]Draft guidanceTechnology appraisal guidance
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]Draft guidanceTechnology appraisal guidance
Nemolizumab for treating prurigo nodularis [ID6451]Draft guidanceTechnology appraisal guidance
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221Draft guidanceTechnology appraisal guidance
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317Draft guidanceTechnology appraisal guidance
Pembrolizumab with carboplatin and paclitaxel for untreated advanced or recurrent endometrial cancer [ID6381]Draft guidanceTechnology appraisal guidance
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369]Draft guidanceTechnology appraisal guidance
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]Draft guidanceTechnology appraisal guidance
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]Draft guidanceTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All